CRL vs. DGX
Compare and contrast key facts about Charles River Laboratories International, Inc. (CRL) and Quest Diagnostics Incorporated (DGX).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: CRL or DGX.
Key characteristics
| CRL | DGX | |
|---|---|---|
| YTD Return | -8.65% | 19.80% |
| 1Y Return | 27.00% | 24.80% |
| 3Y Return (Ann) | -17.66% | 4.83% |
| 5Y Return (Ann) | 9.46% | 11.88% |
| 10Y Return (Ann) | 13.01% | 12.33% |
| Sharpe Ratio | 0.70 | 1.22 |
| Sortino Ratio | 1.25 | 1.95 |
| Omega Ratio | 1.16 | 1.23 |
| Calmar Ratio | 0.41 | 0.98 |
| Martin Ratio | 1.36 | 4.64 |
| Ulcer Index | 18.80% | 5.25% |
| Daily Std Dev | 36.56% | 20.03% |
| Max Drawdown | -69.81% | -49.46% |
| Current Drawdown | -52.88% | -0.17% |
Fundamentals
| CRL | DGX | |
|---|---|---|
| Market Cap | $11.29B | $17.79B |
| EPS | $8.01 | $7.44 |
| PE Ratio | 27.55 | 21.42 |
| PEG Ratio | 2.84 | 1.86 |
| Total Revenue (TTM) | $4.06B | $9.54B |
| Gross Profit (TTM) | $1.37B | $3.08B |
| EBITDA (TTM) | $924.19M | $1.82B |
Correlation
The correlation between CRL and DGX is 0.34, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
Performance
CRL vs. DGX - Performance Comparison
In the year-to-date period, CRL achieves a -8.65% return, which is significantly lower than DGX's 19.80% return. Over the past 10 years, CRL has outperformed DGX with an annualized return of 13.01%, while DGX has yielded a comparatively lower 12.33% annualized return. The chart below displays the growth of a $10,000 investment in both assets, with all prices adjusted for splits and dividends.
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
CRL vs. DGX - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Charles River Laboratories International, Inc. (CRL) and Quest Diagnostics Incorporated (DGX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Dividends
CRL vs. DGX - Dividend Comparison
CRL has not paid dividends to shareholders, while DGX's dividend yield for the trailing twelve months is around 1.83%.
| TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
CRL Charles River Laboratories International, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
DGX Quest Diagnostics Incorporated | 1.83% | 2.02% | 2.08% | 1.40% | 1.85% | 1.99% | 2.34% | 1.83% | 1.72% | 2.07% | 1.92% | 2.24% |
Drawdowns
CRL vs. DGX - Drawdown Comparison
The maximum CRL drawdown since its inception was -69.81%, which is greater than DGX's maximum drawdown of -49.46%. Use the drawdown chart below to compare losses from any high point for CRL and DGX. For additional features, visit the drawdowns tool.
Volatility
CRL vs. DGX - Volatility Comparison
Charles River Laboratories International, Inc. (CRL) has a higher volatility of 15.62% compared to Quest Diagnostics Incorporated (DGX) at 7.59%. This indicates that CRL's price experiences larger fluctuations and is considered to be riskier than DGX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Financials
CRL vs. DGX - Financials Comparison
This section allows you to compare key financial metrics between Charles River Laboratories International, Inc. and Quest Diagnostics Incorporated. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities